Nanotechnology and cancer-An overview

International Journal of Pharma and Bio Sciences

Volumn 1, Issue 4, 2010, Pages

  Balaji, Subbiah ^b   Parimala Devi, B ^a  

^a SASTRA UNIVERSITY   (India)

^b HINDUSTHAN COLLEGE OF ARTS AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 5 ACETAMIDOSALICYLIC ACID; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; DENDRIMER; DICLOFENAC; DOCETAXEL; FLUOROURACIL; GOLD NANOPARTICLE; LIPOSOME; MAGNETIC NANOPARTICLE; MEFENAMIC ACID; NANOPARTICLE; PACLITAXEL; PHOTOFRIN; PHOTOSENSITIZING AGENT; POLYMER; PROPOFOL; PYRIDINE; QUANTUM DOT; VERTEPORFIN;

ARTICLE; BIOCOMPATIBILITY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CONTROLLED DRUG RELEASE; CRITICAL MICELLE CONCENTRATION; CRYOSURGERY; DIGESTIVE SYSTEM CANCER; DNA BINDING; DRUG CLEARANCE; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; LIPOSOMAL DELIVERY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NANOANALYSIS; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NEOPLASM; NEUTRON CAPTURE THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; SOLID TUMOR;

EID: 84455208546     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Oyewumi, M. O. & Mumper, R. J. (2004). Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J.Control. Rel.24, 613-626
2. Neuwalt E. A. et al. Imaging of iron oxide nanoparticles with MR and light microscopy in patients with malignant brain tumors(2004). Neuropathol. Appl. Neurobiol. 5, 456-471
3. Levy, L., Bergey E. J. & Prasad, P. N. Nanochemistry: synthesis and characterization of multifunctional nanoclinics for biological applications(2002). Chem. Mater.14, 3715-3721
4. Bergey, E. J. & Prasad, P. N.DC magnetic field induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro (2002). Biomed. Microdevices 4, 293-299
5. Sullivan, D. & Ferrari, M. Nanotechnology and tumor imaging: seizing an opportunity. Mol. Imaging (in the press)
6. Nashat, A. H., Moronne, M. & Ferrari, M. Detection of functional groups and antibodies on microfabricated surfaces by confocal microscopy (1998). Biotechnol. Bioeng.60, 137-146
7. Yan J F, Liu J, Zhou Y X. Infra red image to evaluate the selective (directional) freezing due to localized injection of thermally important solutions. 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS). Shanghai, China; (2005).
8. Mazur P. The role of intracellular freezing in the death of cells cooled a supra optimal rates. Cryobiology 1977;14: 251-72.
9. Toner M. Nucleation of ice crystals inside biological cells. In Steponkus P,editor. Advances in low-temperature biology. London JAI Press;1993.p.1-51
10. Henderson, B.W., T.M. Buschand J.W. Snyder (2006) Fluencerate as a modulator of PDT mechanisms. Lasers Surg.Med.38, 489-493.
11. Chen, Q., Z. Huang, H. Chen, H. Shapiro, J. Beckers and F.W. Hetzel (2002) Fluencerate effects in photo dynamic therapy of multicell tumor spheroids. Cancer Res. 53, 1249-1254.
12. Foster, T.H., R.S. Murant, R.G. Bryant, R.S. Knox, S.L. Gibson and R. Hilf (1991) Improvement of tumor response by manipulation of tumor oxygenation during photo dynamic therapy. Photochem. Photobiol.76,197-203.
13. Oxygen consumption and diffusion effects in photo dynamic therapy. Radiat. Res. 126, 296-303.
14. Henderson, B.W. and T.J. Dougherty (1992). How does photo dynamic therapy work? Photochem. Photobiol. 55, 145-157.
15. Detty, M. R., S.L. Gibson and S.J. Wagner (2004)Current clinical and pre clinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 47, 3897-3915.
16. Sharman, W.M., C.M. Allen and J.E. van Lier (1999) Photodynamic therapeutics: Basic principles and clinical applications. Drug Discov. Today 4, 507-517
17. Moriwaki, S.I., J. Misawa, Y. Yoshinari, I. Yamada, M. Takigawa and Y. Tokura (2001) Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). Photodermatol. Photoimmunol. Photomed.17, 241-243
18. Azab, M., D.S. Boyer, N.M. Bressler, S.B. Bressler, I. Cihelkova, Y. Hao, I. Immonen, J.I. Lim, U. Menchini, J. Naor, M. J. Potter, A. Reaves, P.J. Rosenfeld, J.S. Slakter, P. Soucek, H.A. Strong, A. Wenkstern, X.Y. Su and Y.C. Yang(2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age related macular degeneration: 2-year results of a randomized clinical trial. Arch.Ophthalmol.123, 448-457
19. Nguyen-Hackley D.H., Ramm E., Taylor C.M., Joung J.K., Dervan P.B., Pabo C.O. (2004) Allosteric inhibition of zincfinger binding in the major groove of DNA by minor groove binding ligands. Biochemistry; 43: 3880-3890.
20. Gopal Y.N.V., Van Dyke M.W. Fechter E.J., Dervan P.B (2003) Combinatorial determination of sequence specificity for nanomolar DNA-binding hairpin polyamides. Biochemistry; 42: 6891-6903.
21. Ellervik U., Wang C.C.C., Dervan P.B. (2000) Allosteric inhibition of protein-DNA complexes by polyamide-intercalator conjugates. J Am Chem Soc; 125: 8476-8485.
22. Kikuta E., Murata M., Katsube N., Koike T., Kimura E. (1999) Hydroxy benzamide/pyrrole pair distinguishes T center dot A from A center dot T basepairs in the minor groove of DNA. J Am Chem Soc; 122: 9354-9360.
23. Novel recognition of thymine base in double-stranded DNA by zinc (II)-macro cyclic tetra amine complexes appended with aromatic groups (2005). J Am Chem Soc; 121: 5426-5436
24. Jantz D., Amann B.T., Gatto G.J., Berg J.M. (2004) The design of functional DNA-binding proteins based on zinc finger domains. Chem Rev; 104: 789-799.
25. Vazquez M.E., Caamano A.M., Mascarenas J.L. Kovacic R.T., Welch J.T., Franklin S.J. (2003) From transcription factors to designed sequence-specific DNA binding peptides. Chem Soc Rev; 32: 338-349.
26. Lajmi A.R., Lovrencic M.E., Wallace T.R., Thomlinson R.R., Shin J.A. (2000) Sequence-selective DNA cleavage by a chimeric metallopeptide. J Am Chem Soc; 125: 6656-6662.
27. Xuereb H., Maletic M., Gildersleeve J., Pelczer I., Kahne D. (2000) Minimalist, alanine - based, helical protein dimmers bind to specific DNA sites. J Am Chem Soc; 122: 5638-5639.
28. Zondlo N.J., Schepartz A. (1999) Design of an oligosaccharide scaffold that binds in the minor groove of DNA. J Am Chem Soc; 122: 1883-1890.
29. Highly specific DNA recognition by a designed miniature protein. J Am Chem Soc; 121: 6938-6939
30. E. Karavas, E. Georgarakis and D. Bikiaris (2006) Adjusting drug release by using miscible polymer blends as effective drug carries, J. Ther Anal Calorimetry 84: 1, 125-133
31. Chen LD, Li Y, Pang DW. Quantum dots and their applications in cancer research. Chin J Cancer (Chinese), 2006, 25: 651-656
32. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol, 2001, 19: 316-317
33. Gao X, Cui Y, Levenson RM, In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol, 2004, 22: 969-976.
34. Gao X, Chung LW, Nie S. Quantum dots for in vivo molecular and cellular imaging. Methods Mol Biol, 2007, 374: 135-146.
35. Yu WW, Chang E, Drezek R,. Watersoluble quantum dots for biomedical applications. Biochem Biophys Res Commun, 2006, 348: 781-786.
36. Weng J, Ren J. Luminescent quantum dots: a very attractive and promising tool in biomedicine. Curr Med Chem, 2006, 13: 897-909.
37. Pradhan N, Battaglia DM, Liu Y,. Efficient, stable, small, and et al watersoluble doped ZnSe nanocrystal emitters as non-cadmium bio- medical labels. Nano Lett, 2007, 7: 312-317.
38. Bentzen EL, Tomlinson ID, Mason J,. Surface modification to reduce nonspecific binding of quantum dots in live cell assays. Bioconjug Chem, 2005, 16: 1488-1494.
39. Yu WW, Chang E, Falkner JC,. Forming biocompatible and non aggregated nanocrystals in water using amphiphilic polymers (2007). J Am Chem Soc, 129: 2871-2879.
40. R. Fernandez-Pacheco, M.R. Ibarra, J.G. Valdivia, C. Marquina, D. Serrate, M.S. Romero, M. Gutiérrez, J. Arbiol (2005) Carbon Coated Magnetic Nanoparticles For Local Drug Delivery using Magnetic Implants, NanoBiotechnology 1: 3: 300-303
41. E. S. Lee, K. Na, and Y. H. Bae. Polymeric micelle for tumor pH and folate-mediated targeting (2003). J. Control. Release. 91: 103-113
42. S.K. Han, K. Na, and Y.H. Bae. Sulfonamide based pH-sensitive polymeric micelles: physico chemical characteristics and pH dependent aggregation (2003). Colloids Surf., A Physicochem. Eng. Asp. 214: 49-59
43. F. Ahmed and D.E. Discher. Selfporating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles (2004). J. Control. Release 96: 37-53
44. I. Bala, S. Hariharan, and M.N. Kumar. PLGA nanoparticles in drug delivery: the state of the art (2004). Crit.Rev. Ther.Drug Carr. Syst.21:387-422.
45. J. Panyamand V. Labhasetwar. Biodegradable nanoparticles for drug and gene delivery to cells and tissue (2003). Adv. Drug Deliv.Rev. 55: 329-347
46. M. Yokoyama, G.S. Kwon, T. Okano, Y. Sakurai, T. Seto, and K. Kataoka. Preparation of micelle-forming polymer-drug conjugates (1992). Bioconjug.Chem. 3: 295-301
47. K. Na, V.A. Sethuraman, and Y.H. Bae. Stimuli-sensitive polymeric micelles as anticancer drug carriers (2006). Anticancer Agents Med.Chem. 6: 525-535
48. S. R. Croy and G.S. Kwon. Polymeric micelles for drug delivery (2006). Curr. Pharm. Des. 12: 4669-4684
49. R. Kim. Recent advances in understanding the cell death pathways activated by anticancer therapy (2005). Cancer 103:1551-1560
50. N.R. Ward well and P.P. Massion. Novel strategies for the early detection and prevention of lung cancer (2005). Semin. Oncol. 32:259-268
51. T. Minko, S.S. Dharap, R.I. Pakunlu, and Y. Wang. Molecular targeting of drug delivery systems to cancer (2004) Current Drug Target 5: 389-406
52. M. Richter and H. Zhang. Receptortargeted cancer therapy (2005). DNA Cell Biol. 24: 271-282
53. C.I. Spiridon, S. Guinn, and E.S. Vitetta. Ac omparison of the in vitro and in vivo activities of IgG and F(ab') 2 fragments of a mixture of three monoclonal anti Her2antibodies (2004).Clin.Cancer Res. 10: 3542-3551
54. S.P. Vyas, A. Singh, and V. Sihorkar. Ligand-receptor mediated drug delivery: an emerging paradigm in cellular drug targeting (2001). Crit. Rev. Ther. Drug Carr. Syst. 18: 1-76
55. V.A. Sethuraman and Y.H. Bae. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors (2006). J.Control.Release 118: 216-224.
56. Müller R. H. (1991) Colloidal Carriers for Controlled Drug Delivery and Targeting, Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, and CRC Press.
57. Boca Raton, FL Cohen S. and Bernstein H. (eds) (1996) Microparticulate Systems for the Delivery of Proteins and Vaccines, Marcel Dekker, New York
58. Lasic D. D. and Martin F. (eds) (1965) Stealth Liposomes, CRC Press.
59. Boca Raton, FL Torchilin V. P. and Trubetskoy V. S. (1995) Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev. 16:141-155
60. Palmer T. N., Caride V. J., Caldecourt M. A., Twickler J. and Abdullah V. (1984) The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta 797:363-368.
61. Maeda H., Wu J., Sawa T., Matsumura Y. and Hori K. (2000) Tumor vascular permeability and the EPR effect in macro-molecular therapeutics: a review. J. Control. Release 65:271-284
62. Torchilin V. P. (1998) Polymer-coated long-circulating microparticular pharmaceuticals. J. Micro encapsul. 15:1-19
63. Mittal K. L. and Lindman B. (eds) (1991) Surfactants in Solution, vols 1-3, Plenum Press, New York.
64. Lasic D. D. (1992) Mixed micelles in drug delivery. Nature 355:279-280.
65. Elworthy P. H., Florence A. T. and Macfarlane C. B. (eds) (1968) Solubilization by Surface Active Agents, Chapman and Hall, London, UK.
66. Attwood D. and Florence A. T. (eds) (1983) Surfactant Systems, Chapman and Hall, London, UK
67. Torchilin V. P. (2001) Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73: 137-172
68. Zhang L. and Eisenberg A. (1995) Multiple morphologies of 'crewcut'aggregates of polystyrene-bpoly(acrylic acid) block copolymers. Science 268: 1728-1731
69. Williams and Wilkins, Baltimore, MD.
70. Gao Z. and Eisenberg A. (1993) A model of micellization for block copolymers in solutions. Macromolecules 26:7353-7360
71. Gao Z. and Eisenberg A. (1993) A model of micellization for block copolymers in solutions. Macromolecules 26:7353-7360
72. Kwon G. S. and Kataoka K. (1995) Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16: 295-309
73. Torchilin V. P. and Trubetskoy V. S. (1996) Biodistribution of surface-modified liposomes and particles. In: Microparticulate Systems for the Delivery of Proteins and Vaccines, Chapt. 8, pp. 243-277.
74. Cohen S. and Bernstein H. (eds). Marcel Dekker, New York
75. Gref R., Domb A., Quellec P., Blunk T., Muller R. H., Verbavatz J. M. et al. (1995) The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16:215-234.
76. Kabanov A. V., Chekhonin V. P., Alakhov V. Yu., Batrakova E. V., Lebedev A. S. and Melik-Nubarov N. S. (1989) The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. FEBS Lett. 258:343-345.
77. Hagan S. A., Coombes A. G. A., Garnett M. C., Dunn S. E., Davies M. C., Illum L. et al. (1996) Polylactide-poly(ethelene glycol) copolymers as drug delivery systems, 1. Characterization of water dispersible micelle-forming systems. Langmuir 12:2153-2161.
78. Inoue T., Chen G., Nakamae K. and Hoffman A. S. (1998) An AB block copolymers of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs. J. Control. Release 51:221-229
79. Hunter J. R. (1991) In: Foundations of Colloid Science, vol.1, Oxford University Press, New York.
80. Kuntz R. M. and Saltzman W. M. (1997) Polymeric controlled delivery for immunization. Trends Biotech. 15:364-369
81. Torchilin VP, Weissing V, editors. Liposomes: a practical approach. 2nd ed. New York: Oxford University Press; 2003.
82. Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin (2007). J Natl Cancer Inst; 99: 1004-15.
83. Igartua M, Saulnier P, Heurtault B, Pech B, Proust JE, Pedraz JL, et al. Development and characterization of solid lipid nanoparticles loaded with magnetite (2002). Int J Pharm; 233: 149-57.
84. Dubes A, Parrot-Lopez H, Abdelwahed W, Degobert G, Fessi H, Shahgaldian P, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins (2003). Eur J Pharm Biopharm; 55: 279-82.
85. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy (1991). Pharm Res;8: 47-54
86. Speiser P, inventor; Dr. Rentschler Arzneimittel GmbH & Co, assignee. Lipid nano-pellets as excipient system for perorally administered drugs. United States patent US 4880634. 1989 Nov 14.
87. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Nonstealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats (2000). Pharmacol Res;42:337-43.
88. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery (2005). J Control Release;109:169-88.
89. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery (2003). J Pharm Sci;92:1343-55.
90. Kwon GS. Polymeric micelles for delivery of poorly water-solubleCompounds (2003). Crit Rev Ther Drug Carrier Syst; 20: 357-403.
91. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery (2005). Mol Biosyst;1: 242-50.
92. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Paraacyl-calixarene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters (2003). Int J Pharm;253:23-38.
93. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles(SLN) for controlled drug delivery: I. Production, characterization, andSterilization (1994). J Control Release;30:83-96.
94. Muller RH, Schwarz C, Mehnert W, Lucks JS. Production of solid lipid nanoparticles (SLN) for controlled drug delivery (1993). Proc Int Symp Control Rel Bioact Mater; 20: 480-1.
95. Tomalia, D.A., Baker, H., Dewald, J.R., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J. & Smith, P. (1985) A new class of polymers: Starburst- dendritic macromolecules. Polym. J. 17, 117-132.
96. Newkome, G.R., Yao, Z.Q., Baker, G.R. & Gupta, V.K. (1985) Cascade molecules: A new approach to micelles, A[27]-arborol. J. Org. Chem. 50, 2003-2006.
97. D.A. Tomalia, I. Majoros, Dendrimeric supramolecular and supramacromolecular assemblies, in: A. Ciferri (Ed.), Supramolecular Polymers, Marcel Dekker, New York, 2000, pp. 359-435.
98. V. Maraval, A.-M. Caminade, J.-P. Majoral, J.-C. Blais, Dendrimer design: how to circumvent the dilemma of a reduction of steps or an increase of function multiplicity? (2003) Angew. Chem., Int. Ed. Engl. 42 1822-1826.
99. E.R. Gillies, J.M.J. Fréchet, Dendrimers and dendritic polymers in drug delivery, (2005) Drug Discov. Today 10 35-42.
100. U. Gupta, H.B. Agashe, A. Asthana, N.K. Jain, Dendrimers: novel polymeric nanoarchitectures for solubility enhancement (2006). Biomacromol. 7 649-658.
101. Y. Cheng, Y. Gao, T. Rao, Y. Li, T. Xu, Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation (2007). Combinat. Chem. High Throughput Screen. 10 336-349.
102. U. Boas, P.M.H. Heegaard, Dendrimers in drug research, Chem. Soc. Rev. 33(2004) 43-63.
103. D.M. Domanski, B. Klajnert, M.Bryszewska, Influence of PAMAM dendrimers on human red blood cells (2004), Bioelectrochemistry 63 189-191.
104. R. Duncan, L. Izzo, Dendrimer biocompatibility and toxicity (2005). Adv. Drug Deliv. Rev. 57 2215-2237.
105. R. Duncan, The dawning era of polymer therapeutics(2003). Nat. Rev. Drug Discov. 2347-359.
106. H.T. Chen, M.F. Neerman, A.R. Parrish, E.E. Simanek, Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery (2004). J. Am. Chem. Soc. 126 10044-10048.
107. D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein, T. Kissel, In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis(2003). Biomaterials 24 1121-1131.
108. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J.W. Weener, E.W. Meijer, W. Paulus, R. Duncan, Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled poly(amidoamine) dendrimers in vivo(2000). J. Control. Release 65 133-148.
109. J. F. G. A. Jansen, E. M. M. de Brabander-van den Berg, E. W. Meijer, Encapsulation of guest molecules into a dendritic box (1994). Science.. 266, 1226-1229.
110. H. Namazi, M. Adeli, Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents (2005). Biomaterials.. 26, 1175-1183.
111. U. Boas, S. H. M. Söntjens, K. J. Jensen, J. B. Christensen, E. W. Meijer, New dendrimer-peptide hostguest complexes: Towards dendrimers as peptide carriers (2002). ChemBioChem. 3, 433-439.
112. A. Córdova, K. D. Janda, Synthesis and catalytic antibody functionalizations of dendrimers. J. Am. Chem. Soc. 2001. 123, 8248-8259.
113. M. T. Morgan, M. A. Carnahan, C. E. Immoos, A. A. Ribeiro, S. Finkelstein, S. J. Lee, M. W. Grinstaff, Dendritic molecular capsules for hydrophobic compounds (2003).J. Am. Chem. Soc. 125, 15 485-15 489.
114. P. K. Tripathi, A. J. Khopade, S. Nagaich, S. Shrivastava, S. Jain, N. K. Jain, Dendrimer grafts for delivery of 5-fluorouracil (2002). Pharmazie. 57, 261-264.
115. T. Ooya, J. Lee, K. Park, Effects of ethylene glycol-based graft, starshaped, and dendritic polymers on solubilization and controlled release of paclitaxel (2003). J. Controlled Release. 93, 121-127.
116. T. Ooya, J. Lee, K. Park, Hydrotropic dendrimers of generations 4 and 5:Synthesis, characterization, and hydrotropic solubilization of paclitaxel (2004). Bioconjugate Chem.. 15, 1221-1229.
117. J. M. Benito, M. Gomez-Garcia, C. Ortiz Mellet, I. Baussanne, J. Defaye, J. M. Garcia Fernandez, Optimizing saccharide-directed molecular delivery to biological receptors: Design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates (2004). J. Am. Chem. Soc.. 126, 10 355-10 363.
118. H. Ringsdorf, Structure and properties of pharmacologically active polymers (1975). J. Polym. Sci. Polym. Symp.. 51, 135-153.
119. H. Bader, H. Ringsdorf, B. Schmidt, Water-soluble polymers in medicine (1984). Angew. Makromol. Chem.. 123/124, 457-485.
120. J. Kopacek, Soluble biomedical polymers (1977). Polym. Med.. 7, 191-221.
121. E. R. Gillies, E. Dy, J. M. J. Fréchet, F. C. Szoka, Biological evaluation of polyester dendrimer: Poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture (2005). Mol. Pharm.. 2, 129-138.
122. P. Kolhe, J. Khandare, O. Pillai, S. Kannan, M. Lieh-Lai, R. M. Kannan, Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload (2006). Biomaterials,. 27, 660-669.